Trulieve in the news

Trulieve is set to become the first U.S. cannabis operator to list on the New York Stock Exchange following federal reclassification of marijuana.

Trulieve authorized a $50 million share repurchase program to return value to shareholders over the next year.

Trulieve is launching a $50 million share buyback program to repurchase and cancel up to 5% of its subordinate voting shares over the next year.

A Florida resident and a citizens group are seeking state intervention over alleged water pollution and erosion caused by a Trulieve cannabis facility.

Trulieve is uplisting to the NYSE after restructuring to separate its medical marijuana operations from its recreational business.

Trulieve is set to become the first U.S. cannabis operator to list on the NYSE by focusing its consolidated business exclusively on state-licensed medical marijuana.

Secured a historic NYSE listing approval following federal reclassification, positioning for expansion in medical marijuana markets and improved capital access.

Georgia is updating its medical cannabis laws to expand patient eligibility and allow for a wider variety of product formats like flower and vapes.

Trulieve is listing its medical cannabis operations on the NYSE after carving out its recreational business to comply with federal regulations and tax laws.

Trulieve is set to become the first U.S. cannabis company to list on the New York Stock Exchange following federal rescheduling.

Trulieve experienced a significant 17.5% stock price increase amid a broad rally across the US cannabis sector and a 3.5% rise in the MSOS benchmark ETF.

Trulieve Cannabis is positioned for growth and a NYSE listing as federal rescheduling of marijuana promises to reduce its tax burden and improve financing access.

Trulieve becomes the first cannabis company to list on the New York Stock Exchange following new federal rule changes.

Trulieve is set to become the first U.S. cannabis company on the NYSE after restructuring its operations following federal medical marijuana rescheduling.

Trulieve is making history as the first U.S. cannabis operator to list on the NYSE by spinning off its recreational business to meet regulatory requirements.

Trulieve is uplisting to the New York Stock Exchange following federal reclassification of medical marijuana to Schedule III.

Trulieve is uplisting to the NYSE after restructuring its business to separate recreational and medical operations following federal reclassification of cannabis.

Trulieve is set to become the first U.S. cannabis operator on the NYSE by restructuring as a medical-only entity to comply with exchange rules and federal Schedule III reclassification.

Trulieve is moving its stock listing to the New York Stock Exchange to improve investor access and market liquidity.

Trulieve will begin trading on the New York Stock Exchange on June 10, 2026, following its successful application and federal rescheduling of medical cannabis.